Scott H S, Litjens T, Nelson P V, Thompson P R, Brooks D A, Hopwood J J, Morris C P
Department of Chemical Pathology, Adelaide Children's Hospital, Australia.
Am J Hum Genet. 1993 Nov;53(5):973-86.
Mucopolysaccharidosis type I (MPS-I) is an autosomal recessive genetic disease caused by a deficiency of the lysosomal glycosidase alpha-L-iduronidase. Hurler (severe), Scheie (mild), and Hurler/Scheie (intermediate) syndromes are clinical subtypes of MPS-I, but it is difficult to distinguish between these subtypes by biochemical measurements. Mutation analysis was undertaken to provide a molecular explanation for the clinical variation seen in MPS-I. Using chemical cleavage and direct PCR sequencing, we have defined four previously undescribed mutations for MPS-I (delG1702, 1060 + 2t-->c, R89Q, and 678-7g-->a). R89Q and 678-7g-->a were found to be present in 40% of Scheie syndrome alleles. Expression of R89Q demonstrated reduced stability and activity of the mutant protein. The deleterious effect of R89Q may be potentiated by a polymorphism (A361T) to produce an intermediate phenotype. 678-7g-->a was found to be a mild mutation, since it was present in an index Scheie syndrome patient in combination with a severe allele (W402X). This mutation appears to allow a very small amount of normal mRNA to be produced from the allele which is likely to be responsible for the mild clinical phenotype observed. Both the 5' and 3' splice site mutations (1060 + 2t-->c and 678-7g-->a, respectively) result in high proportions of mature mRNAs containing introns, which has not been observed for other splicing mutations. The frameshift mutation (delG1702) and the 5' splice site mutation (1060 + 2t-->c) are both thought to be associated with severe MPS-I. The identification of these MPS-I mutations begins to document the expected genetic heterogeneity in MPS-I and provides the first molecular explanations for the broad range of clinical phenotypes observed.
I型黏多糖贮积症(MPS-I)是一种常染色体隐性遗传病,由溶酶体糖苷酶α-L-艾杜糖醛酸酶缺乏引起。胡勒(重度)、谢伊(轻度)和胡勒/谢伊(中度)综合征是MPS-I的临床亚型,但通过生化检测很难区分这些亚型。进行突变分析是为了从分子层面解释MPS-I中出现的临床变异情况。通过化学切割和直接PCR测序,我们确定了4个此前未描述过的MPS-I突变(delG1702、1060 + 2t→c、R89Q和678-7g→a)。发现R89Q和678-7g→a存在于40%的谢伊综合征等位基因中。R89Q的表达显示突变蛋白的稳定性和活性降低。R89Q的有害作用可能因一种多态性(A361T)而增强,从而产生中间表型。发现678-7g→a是一个轻度突变,因为它存在于一名索引谢伊综合征患者中,且与一个重度等位基因(W402X)同时出现。该突变似乎能使该等位基因产生极少量的正常mRNA,这可能是观察到的轻度临床表型的原因。5'和3'剪接位点突变(分别为1060 + 2t→c和678-7g→a)导致大量成熟mRNA含有内含子,这在其他剪接突变中尚未观察到。移码突变(delG1702)和5'剪接位点突变(1060 + 2t→c)都被认为与重度MPS-I相关。这些MPS-I突变的鉴定开始记录MPS-I中预期的遗传异质性,并为观察到的广泛临床表型提供了首个分子层面的解释。